US › Healthcare

Crispr Therapeutics AG (CRSP)

US · Healthcare · Biotechnology

$53.07+7.06%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$1.5M
Revenue YoY
+68.6%
Net profit
$-122.9M
Profit YoY
+9.6%
EPS
$-1.28
EPS estimate
$-1.23
Net margin
-8,431.5%

EPS came in at -1.28 against a street estimate of -1.23 — a miss of 4.1%.

Key statistics

Market cap
$4.73B
Forward P/E
23.4
P/B
2.60
Book value
$18.83
EPS (TTM)
$-6.17
52-week high
$78.48
52-week low
$44.12
50-day MA
$52.21
200-day MA
$54.04
Beta
1.74

Analyst view

Analysts rate Crispr Therapeutics AG a buy (17 buy, 10 hold, 1 sell out of 28) with an average price target of $86.78.

Shareholding

Insiders
5.91%
Institutions
79.42%

Largest institutional holders

FundStake
ARK Investment Management LLC11.49%
BlackRock Inc7.80%
Orbis Allan Gray Ltd6.20%
Capital World Investors4.80%
State Street Corp4.04%
GSK PLC3.27%
T. Rowe Price Investment Management,Inc.3.00%
Geode Capital Management, LLC2.41%

Recent filings & reports

DocumentDate
Board / officer change · Q2 20262026-06-04
Quarterly report · Q1 20262026-05-04
Results announced · Q2 20262026-05-04
Proxy statement · Q2 20262026-04-21
Material agreement · Q1 20262026-03-16
Company announcement · Q1 20262026-03-11
Annual report FY20252026-02-12
Quarterly report · Q3 20252025-11-10

Readable in the app.

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Crispr Therapeutics AG — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.